MYOS RENS Technology Inc.

61 articles about MYOS RENS Technology Inc.

• MYOS CORP, Formerly Known as Myos Rens Technology, Inc., Issues Notice to its Shareholders

  12/15/2020

   MYOS CORP ("MYOS" or the "Company"),  is a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health . MYOS is the sole owner of Fortetropin ® ,  a proprietary advanced nutrition product developed and owned by MYOS, that has been shown in multiple veterinary and human cli

• MedAvail and MYOS RENS Technology Announce Closing of Business Combination

  11/18/2020

  MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an adva

• MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding

  11/17/2020

   MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020 , MYOS RENS Technology, Inc., a Nevada corporation ("MYOS"), and MedAvail, Inc

• MYOS RENS Technology Announces Net Revenues Increase 39% for the Three Months Ended September 30, 2020

  11/6/2020

  MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today its results fo

• MYOS RENS Technology, Inc. Appoints The S3 Agency to Help Build Awareness of Muscle Health Importance

  9/9/2020

  MYOS RENS Technology, Inc. ("MYOS") (NASDAQ: MYOS), "The Muscle Health Company" and owner of the advanced nutrition supplement Fortetropin®, announced today that it has hired The S3 Agency (S3)

• MYOS RENS Technology's Net Revenues Increase 114% and Operating Expenses Decrease 26% for the Three Months Ended June 30, 2020

  8/5/2020

  For the six months ended June 30, 2020, Net Revenues Increase 104% and Operating Expenses Decrease by 17% Peer-Reviewed Research Published, Launch of AAVSB-Accredited Veterinary Continuing Education Program and Wide-Ranging Distribution Agreements with Key Partners Lay the Foundation for Sustained Growth.

• MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.

  7/16/2020

  MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has settled its pending litigation with RENS Technology Inc. and its president,

• University of California, Berkeley Researchers Publish Clinical Results Reporting that Fortetropin® Increased the Rate of Muscle Protein Synthesis in Older Adults

  7/7/2020

  MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today, the publication of a study that evaluated the impact of Fortetropin on the rate of muscle protein synthesis in older adults.

• MYOS RENS Technology and MedAvail Inc. Announce Merger and Spin-Out of Muscle Health Business

  6/30/2020

  MYOS RENS Technology, Inc. ("MYOS") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, and MedAvail, Inc. ("MedAvail"), a private, in-clinic telemedicine-enabled pharmacy organization that has developed and commercialized a proprietary robotic dispensing platform and home delivery operation focused on the Medicare Advantage market in the United States,

• MYOS RENS Launches RACE-Approved Continuing Education Course for Veterinarians on June 10, 2020

  6/4/2020

   MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today that it wi

• MYOS RENS Partners with GetHealthy.store to Promote MYOS Longevity's Clinically-Backed Nutrition Products

  5/21/2020

  GetHealthy Network Hosts E-Commerce Supplement Stores with a Network of Over 1,000 Medical Practitioners Nationwide

• MYOS RENS Enters into Agreement with Victor Medical to Distribute MYOS Canine Muscle Formula® Across Western United States

  5/14/2020

  Agreement Will Enable MYOS to Significantly Expand the Reach of its Veterinary Business

• MYOS RENS Technology Reports First Quarter 2020 Financial Results Including a 95% Increase in Net Revenues

  5/8/2020

  Myosrens to host conference call today

• MYOS RENS Technology Announces the Date for First Quarter 2020 Conference Call and Webcast

  5/4/2020

  MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, will announce financial results for the first quarter of 2020 on Friday, May 8, 2020 at 11:30 AM ET .

• MYOS RENS Announces Publication of Landmark Clinical Study on Recovery in Dogs Following TPLO Surgery

  4/15/2020

  MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced the publication of a study that concluded that the use of Fortetropin decreased muscle atrophy in dogs following tibial-plateau leveling osteotomy (TPLO).

• MYOS RENS Technology Reports a 187% Increase in Net Revenues for the Year Ended December 31, 2019

  3/25/2020

  Closed $1.8 million of financing in a Private Placement on March 5, 2020 Company to Hold Conference Call on Wednesday, March 25, 2020, at 11am ET Conference Call Dial In: 877-407-9120 from the U.S.; international callers may telephone 412-902-1009 approximately 15 minutes before the call.   [25-March-2020]   CEDAR KNOLLS, N.J. , March 25, 2020 /PRNewsw

• MYOS RENS Technology Announces Date of Fourth Quarter 2019 Financial Results, Conference Call and Webcast

  3/19/2020

  MYOS RENS Technology Inc. will announce financial results for the fourth quarter of 2019 on Wednesday, March 25 at 11 AM (ET

• MYOS RENS Technology to Provide Exciting Updates on New Product and Clinical Research at the Veterinary Meeting & Expo in Orlando, January 19-22, 2020

  1/15/2020

  One-of-a Kind Product Backed by Clinical Science Improves Muscle Health in Dogs

• MYOS RENS' Fortetropin® Clinical Trial Results to be Presented by William J. Evans, Ph.D., at the International Conference on Frailty and Sarcopenia Research

  11/20/2019

  MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), announced today that an abstract based on the results from a clinical trial evaluating the impact of Fortetropin

• MYOS RENS Technology Reports Third Quarter 2019 Financial Results Including Year-Over-Year Revenue Growth of 430%

  11/7/2019

  MYOS RENS Technology Inc., an advanced nutrition company and the owner of Fortetropin®, an innovative proprietary bioactive composition made from fertilized egg yolks that helps build lean muscle, announced its financial results for the three and nine months ended September 30, 2019.